Bansi 1996.

Methods	Randomised clinical trial.
Participants	Country: UK. Number randomised: 23. Post‐randomisation drop‐outs: 1 (4.3%). Revised sample size: 22. Mean age: 53 years. Females: 7 (31.8%). Separate data for the subgroup with ulcerative colitis: no. Inclusion criteria: Diagnosis of primary sclerosing cholangitis. Pre‐trial biopsy and cholangiography. Exclusion criteria: not stated. Follow‐up: 12 months.
Interventions	Participants were randomly assigned to 1 of 2 groups. Group 1: moderate‐dose UDCA (20 mg/kg/d) over the period of follow‐up of the study (n = 11). Group 2: placebo over the period of follow‐up of the study (n = 11).
Outcomes	No outcomes of interest were reported.
Notes	Reasons for post‐randomisation drop‐out: Dominant bile duct stricture that required stenting (UDCA group).
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: This information was not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "Double‐blind placebo‐controlled trial". Comment: Further details were not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available.
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: Post‐randomisation drop‐outs may be related to the treatment that participants received.
Selective reporting (reporting bias)	Unclear risk	Comment: No published protocol was available; no outcomes of interest were reported.
For‐profit bias	Unclear risk	Comment: This information was not available.
Other bias	Low risk	Comment: no other bias.